Gold prices steady ahead of Fed decision, Trump’s tariff deadline
MARLBOROUGH, Mass. - Boston Scientific Corporation (NYSE: BSX), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $140.6 billion, today announced a significant change in its executive team, with the upcoming retirement of Dan Brennan, the company’s executive vice president and chief financial officer. Brennan, who has been with the company for nearly three decades, will step down from his CFO role at the end of June and serve as a senior advisor until early October 2025. According to InvestingPro data, the company has demonstrated strong financial performance with a 37.7% total return over the past year.
Mike Mahoney, chairman and chief executive officer of Boston Scientific, expressed his gratitude for Brennan’s leadership and contributions, highlighting his role in the company’s financial transformation and culture building. Under their leadership, the company has achieved impressive revenue growth of 17.6% in the last twelve months, with total revenue reaching $16.7 billion. Brennan has been with Boston Scientific since 2014, playing a pivotal role in strategic investments and talent development within the financial organization. InvestingPro analysis reveals the company maintains a strong financial health score, with particularly high marks in profitability metrics.
Jon Monson, the current senior vice president of Investor Relations, is set to take over as executive vice president and CFO on June 30, 2025. Monson, who has been with the company for over 25 years, brings a wealth of financial experience from various roles, including global controller and chief accounting officer. He is recognized for his strategic approach and leadership during challenging financial times, such as the 2020 pandemic.
Boston Scientific is a global medical technology leader that has been innovating in the field for over 45 years. The company focuses on developing medical solutions that improve patient health and reduce healthcare costs. Its product portfolio aids physicians in diagnosing and treating complex diseases across several medical specialties. With a robust gross profit margin of 68.4% and strong cash flows, the company demonstrates operational excellence. For deeper insights into Boston Scientific’s financial health and growth prospects, InvestingPro subscribers can access 13 additional exclusive ProTips and comprehensive valuation metrics in the Pro Research Report.
This leadership transition is part of the company’s forward-looking statements, which involve risks and uncertainties that could cause actual results to differ materially from those projected. These statements are based on current beliefs and assumptions and are not guarantees of future performance.
The information in this article is based on a press release statement from Boston Scientific Corporation.
In other recent news, Boston Scientific is poised to release its first-quarter earnings, with analysts from TD Cowen expecting the company to exceed its earnings projections. The anticipated earnings per share (EPS) is set between $0.66 and $0.68, alongside reported and organic revenue growth estimates of 17-19% and 14-16%, respectively. Analysts from Needham have upgraded Boston Scientific’s stock to a Buy rating, with a new price target of $113, citing reduced competitive threats and potential revenue growth from the WATCHMAN device. The company’s recent acquisitions, including Bolt Medical and SoniVie, are highlighted as avenues for future expansion. RBC Capital Markets maintains an Outperform rating with a $116 price target, emphasizing Boston Scientific’s resilience to economic challenges and its strong product demand. The firm expects the company to potentially exceed its 2025 financial guidance, driven by innovations in medical technology. These developments reflect a positive outlook from multiple analysts, with Boston Scientific’s strategic initiatives and product advancements being key factors in its projected growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.